Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Atrium Therapeutics, Inc. (RNA) had Revenue of 19.64M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	19.64M
Net Income	-16.63M
Cost of Goods Sold	--
Gross Profit	19.64M
Operating Expenses	36.91M
Operating Income	-17.28M
Non-Operating Income/Expense	0.65M
Pre-Tax Income	-16.63M
Normalized Pre-Tax Income	-16.63M
Income after Taxes	-16.63M
Income from Continuous Operations	-16.63M
Consolidated Net Income/Loss	-16.63M
Normalized Income after Taxes	-16.63M
EBIT	-17.28M
EBITDA	-17.13M
Weighted-Average Shares Outstanding (Basic)	17.11M
Weighted-Average Shares Outstanding (Diluted)	17.11M
Earnings per Share (EPS) (Basic)	-0.97
Earnings per Share (EPS) (Diluted)	-0.97
Balance Sheet Financials
Current Assets	285.56M
Property, Plant, and Equipment	4.34M
Long-Term Assets	6.79M
Total Assets	292.36M
Current Liabilities	21.91M
Long-Term Debt	--
Long-Term Liabilities	36.35M
Total Liabilities	58.26M
Common Equity	234.10M
Tangible Shareholders Equity	234.10M
Shareholders Equity	234.10M
Common Shares Outstanding	17.11M
Cash Flow Statement Financials
Cash Flow from Operating Activities	-31.14M
Cash Flow from Investing Activities	-2.10M
Cash Flow from Financial Activities	301.50M
Beginning Cash	--
End Cash	268.26M
Increase/Decrease in Cash	268.26M
Stock-Based Compensation	12.21M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	13.04
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	100.00%
Operating Margin	-88.01%
EBIT Margin	-88.01%
EBITDA Margin	--
Pre-Tax Profit Margin	-84.71%
Profit Margin	-84.71%
Free Cash Flow	-33.24M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.07
Inventory Turnover	--
Receiveable Turnover	1.31
Days Sales in Receivables	68.75
Return on Equity	-7.11%
Return on Tangible Equity	-7.11%
Return on Assets	-5.69%
Return on Investments	-7.11%
Book Value Per Share	13.69
Free Cash Flow per Share	-1.94
Operating Cash Flow per Share	-1.82

Data from Zacks Investment Research, Inc.